MARKET WIRE NEWS

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript

Source: SeekingAlpha

2025-05-06 23:13:47 ET

Rigel Pharmaceuticals, Inc. (RIGL)

Q1 2025 Earnings Conference Call

May 06, 2025, 04:30 PM ET

Company Participants

Ray Furey - Executive Vice President, General Counsel & Corporate Secretary.

Raul Rodriguez - President & Chief Executive Officer

Dave Santos - Chief Commercial Officer

Lisa Rojkjaer - Chief Medical Officer

Dean Schorno - Chief Financial Officer

Conference Call Participants

Kalpit Patel - B. Riley Securities

Joe Pantginis - H.C. Wainwright

Farzin Haque - Jefferies

Presentation

Operator

Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2025. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Fury. You may begin.

Ray Furey

Welcome to our first quarter 2025 financial results and business update conference call. The financial press release for the first quarter 2025 was issued a short while ago and can be viewed along with the slides for this presentation in the News and Events section of our Investor Relations site on rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC, including our quarter one quarterly report on Form 10-Q on file with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul?

Raul Rodriguez

Thank you, Ray, and thank you, everyone, for joining today. Also with us today are Dave Santos, our Chief Commercial Officer; Lisa Rojkjaer, our Chief Medical Officer; and Dean Schorno, our Chief Financial Officer....

Read the full article on Seeking Alpha

For further details see:

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
Rigel Pharmaceuticals Inc.

NASDAQ: RIGL

RIGL Trading

-3.13% G/L:

$26.0825 Last:

96,605 Volume:

$26.87 Open:

mwn-alerts Ad 300

RIGL Latest News

RIGL Stock Data

$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App